Kelly WM - Search Results

1

Idiopathic hypertrophic cranial pachymeningitis. Report of three cases.

Mamelak AN, Kelly WM, Davis RL, Rosenblum ML. Mamelak AN, et al. Among authors: kelly wm. J Neurosurg. 1993 Aug;79(2):270-6. doi: 10.3171/jns.1993.79.2.0270. J Neurosurg. 1993. PMID: 8331412 Review.

2

Radiographic assessment of discogenic disease of the spine.

Vanderburgh DF, Kelly WM. Vanderburgh DF, et al. Among authors: kelly wm. Neurosurg Clin N Am. 1993 Jan;4(1):13-33. Neurosurg Clin N Am. 1993. PMID: 8428148 Review.

3

Common artifacts encountered in magnetic resonance imaging.

Clark JA 2nd, Kelly WM. Clark JA 2nd, et al. Among authors: kelly wm. Radiol Clin North Am. 1988 Sep;26(5):893-920. Radiol Clin North Am. 1988. PMID: 3420238

4

Isolated abducens nerve palsy: MR imaging findings.

Depper MH, Truwit CL, Dreisbach JN, Kelly WM. Depper MH, et al. Among authors: kelly wm. AJR Am J Roentgenol. 1993 Apr;160(4):837-41. doi: 10.2214/ajr.160.4.8456676. AJR Am J Roentgenol. 1993. PMID: 8456676

5

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.

Nixon AB, Liu Y, Yang Q, Luo B, Starr MD, Brady JC, Kelly WK, Beltran H, Morris MJ, George DJ, Armstrong AJ, Halabi S. Nixon AB, et al. Prostate Cancer Prostatic Dis. 2024 Feb 12. doi: 10.1038/s41391-024-00794-3. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38347114

6

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.

Gordon N, Gallagher PT, Neupane NP, Mandigo AC, McCann JK, Dylgjeri E, Vasilevskaya I, McNair C, Paller CJ, Kelly WK, Knudsen KE, Shafi AA, Schiewer MJ. Gordon N, et al. bioRxiv [Preprint]. 2023 Mar 23:2023.03.23.533944. doi: 10.1101/2023.03.23.533944. bioRxiv. 2023. PMID: 36993449 Free PMC article. Preprint.

7

Predictors of consenting to participate in a clinical trial among urban cancer patients.

McIntire RK, Keith SW, Nowlan T, Butt S, Cambareri K, Callaghan J, Halstead T, Chandrasekar T, Kelly WK, Leader AE. McIntire RK, et al. Contemp Clin Trials. 2023 Feb;125:107061. doi: 10.1016/j.cct.2022.107061. Epub 2022 Dec 22. Contemp Clin Trials. 2023. PMID: 36567059

8

Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.

Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D, Szmulewitz R, Sartor O, Knudsen K, Yang ES, Kelly WK. Quinn Z, et al. Clin Cancer Res. 2023 Jan 4;29(1):50-59. doi: 10.1158/1078-0432.CCR-22-2526. Clin Cancer Res. 2023. PMID: 36321991 Free PMC article. Clinical Trial.

9

To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence.

Halabi S, Carthon BC, Kelly WK. Halabi S, et al. JAMA Oncol. 2022 Aug 1;8(8):1137-1138. doi: 10.1001/jamaoncol.2022.1623. JAMA Oncol. 2022. PMID: 35708731 Free PMC article. No abstract available.

10

Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysis.

Awasthi S, Mahal BA, Park JY, Creed JH, Williams VL, Elkenawi A, Meadows SO, Pow-Sang JM, Lu-Yao G, Kelly WK, Lang DY, Zgibor J, Rebbeck TR, Yamoah K. Awasthi S, et al. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):547-552. doi: 10.1038/s41391-022-00510-z. Epub 2022 Feb 23. Prostate Cancer Prostatic Dis. 2022. PMID: 35194179 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page